OTLK Outlook Therapeutics Net earnings per share (EPS TTM)

OTLK (Outlook Therapeutics, Inc.) - company brandmark

Outlook Therapeutics is a biopharmaceutical innovator that created Lytenava for the treatment of macular degeneration and is developing ophthalmological antibodies. The GURU.Markets website features a moving average trend for earnings per share, where the parameter value reaches 0.00. High business scalability promises excess returns upon the global replication of patents, while the current strategy focuses on the commercial launch of the drug and the deployment of B2B sales in the US and Europe.

OTLK Outlook Therapeutics Net earnings per share for the last four quarters (07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Outlook Therapeutics (OTLK)

Summary company analytics:OTLK - Outlook Therapeutics, Inc.
Flagship merchandise of Outlook Therapeutics Corp

This indicator represents the total net income of Outlook Therapeutics (OTLK) over the last twelve months, distributed per common share. This metric allows for an assessment of the business's real profitability by excluding the volatility of one-off quarterly reports. By analyzing the net income per share TTM, an investor can observe the dynamics of the capital's fundamental value. For Outlook Therapeutics (OTLK), this result depends directly on the efficiency of managing substance logistics costs. Stability of supplies through diversified corridors minimizes operational risks, supporting the resilience of this financial metric.

Competitor analysis for Outlook Therapeutics